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Abstract Human cytomegalovirus (HCMV) is a highly prevalent pathogen that induces life-long
infections notably through the establishment of latency in hematopoietic stem cells (HSC). Bouts of
reactivation are normally controlled by the immune system, but can be fatal in immuno-compromised
individuals such as organ transplant recipients. Here, we reveal that HCMV latency in human CD34+
HSC reflects the recruitment on the viral genome of KAP1, a master co-repressor, together with HP1
and the SETDB1 histone methyltransferase, which results in transcriptional silencing. During lytic
infection, KAP1 is still associated with the viral genome, but its heterochromatin-inducing activity is
suppressed by mTOR-mediated phosphorylation. Correspondingly, HCMV can be forced out of
latency by KAP1 knockdown or pharmacological induction of KAP1 phosphorylation, and this process
can be potentiated by activating NFkB with TNF-α. These results suggest new approaches both to
curtail CMV infection and to purge the virus from organ transplants.
DOI: 10.7554/eLife.06068.001
Introduction
Human cytomegalovirus (HCMV), a member of the β-herpes virus family, is a highly prevalent
pathogen that induces life-long infections notably through the establishment of latency in
hematopoietic stem cells (HSC) (Sinclair, 2008). Bouts of reactivation are normally asymptomatic
because rapidly controlled by the immune system, but can be fatal in immuno-compromised
individuals such as AIDS patients and transplant recipients, in particular when grafts from HCMV-
positive donors are given to HCMV-negative individuals (Sissons and Carmichael, 2002).
Furthermore, primary HCMV infection during pregnancy is a leading cause of congenital
malformations of the central nervous system (Britt, 2008).
The approximately 250 kb genome of HCMV encodes several hundred proteins, some 14 miRNAs and
a few long-noncoding RNAs (Stern-Ginossar et al., 2012). Infection of permissive targets such as
epithelial cells or fibroblasts leads to a lytic cycle, with a highly orderly transcriptional cascade that first
expresses the viral immediate early (IE) genes, the products of which set the cellular stage for the virus and
activate the viral early (E) genes. These yield the effectors of viral genome replication, before proteins
encoded by the viral late (L) genes finally trigger the formation of new particles. In contrast, when HCMV
infects a HSC, the expression of lytic genes is rapidly suppressed and only a few latency-associated
transcripts are detected (Goodrum et al., 2012). The viral genome is then maintained as a stable episome,
without replicating or producing new virions (Goodrum et al., 2004). When HCMV-infected HSC are
differentiated in vitro into dendritic cells (DCs) and these are induced to mature, the virus resumes a lytic
cycle. Accordingly, blood CD14+monocytes, which are circulating precursors of DCs, harbor latent HCMV.
HCMV reactivation is thus tightly coupled with myeloid differentiation. However, the molecular
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be associated with epigenetic modifications of the viral chromatin (Avdic et al., 2011; Umashankar
et al., 2011;Mason et al., 2012; Petrucelli et al., 2012). In latently infected CD34+ HSC or circulating
monocytes isolated from seropositive individuals, chromatin at the major immediate early promoter
(MIEP) bears histone 3 trimethylated on lysine 9 (H3K9me3), a repressive mark, and heterochromatin
protein 1 (HP1) (Sinclair, 2010; Reeves and Sinclair, 2013). Upon differentiation of latently infected
precursors into dendritic cells, H3K9me3 is replaced by high levels of histone acetylation, HP1 is lost,
and a lytic cycle is triggered (Taylor-Wiedeman et al., 1994; Mendelson et al., 1996; Hahn et al.,
1998; Reeves et al., 2005).
KAP1 (KRAB-associated protein 1), also known as TRIM28 (tripartite motif protein 28) or TIF1β
(transcription intermediary factor 1 beta) is a transcriptional co-repressor essential for the early
embryonic silencing of endogenous retroelements (Rowe et al., 2010; Castro-Diaz et al., 2014;
Turelli et al., 2014) and involved in regulating multiple aspects of mammalian homeostasis, including
in the hematopoietic system (Jakobsson et al., 2008; Bojkowska et al., 2012; Chikuma et al., 2012;
Santoni de Sio et al., 2012a, 2012b; Barde et al., 2013). KAP1 binds to the Kru¨ppel-associated box
(KRAB) domain present at the N-terminus of KRAB-containing zinc finger proteins (KRAB-ZFPs)
(Friedman et al., 1996). These constitute the single largest family of transcriptional repressors
encoded by the genomes of higher organisms, with close to four-hundred members in either human
or mouse, and are endowed with sequence-specific DNA binding ability via a C-terminal array of zinc
fingers (Urrutia, 2003). KAP1 harbors from its N- to its C-terminus a RING finger, B-boxes, a coiled-
coil region, a HP1-binding motif, a PHD finger and a bromodomain (Iyengar and Farnham, 2011).
The first three of these motifs define the so-called RBCC or TRIM (tripartite motif) region, which is
both necessary and sufficient for homo-oligomerization and direct binding to KRAB. The C-terminal
effector end of the protein recognizes the backbone of histone tails, and interacts with two histone-
modifying enzymes: Mi2α, an isoform of the Mi2 protein found in the NuRD (nucleosome remodeling
and histone deacetylation) complex (Schultz et al., 2001), and SETDB1 (SET domain, bifurcated 1),
an H3K9me3-specific histone methyltransferase (Schultz et al., 2002). The H3K9me3 mark in turn
creates high affinity genomic binding sites for HP1, bringing more KAP1 complex, which likely explains
that KAP1-induced heterochromatin formation can spread several tens of kilobases away from an initial
eLife digest Human cytomegalovirus (HCMV) is an extremely common virus that causes life-long
infections in humans. Most individuals are exposed to HCMV during childhood, and the infection
rarely causes any symptoms of disease in healthy individuals. However, in people with weaker
immune systems—for example, newborn babies, people with AIDS, or individuals who have received
an organ transplant—HCMV can cause life-threatening illnesses.
It is difficult for the immune system to fight the infection because HCMV is able to hide in cells
within the bone marrow called hematopoietic stem cells. Inside these cells, the virus can survive in
a ‘dormant’ state for many years, before being reactivated and starting to multiply again. In most
people, the immune system manages to control this new outbreak of HCMV, and the virus becomes
dormant again, but reactivation of the virus in individuals with weakened immune systems is much
more likely to cause serious illness.
The results of previous studies suggest that when HCMV infects the hematopoietic stem cells,
human proteins switch off the expression of many virus genes, which makes the virus inactive. The
virus can be reactivated when infected stem cells change into a type of immune cell called dendritic
cells, but it is not clear how this is controlled.
Here, Rauwel et al. reveal that a human protein called KAP1 is responsible for switching off the
virus genes in the stem cells. It does so by interacting with two other proteins to alter the structure of
the DNA in these genes. However, if the stem cells are stimulated to change into dendritic cells,
KAP1 becomes inactive, which allows the virus genes to be switched on.
Rauwel et al. also show that it is possible to force HCMV out of its dormant state by using drugs to
block the activity of KAP1. This may aid the development of treatments that prevent the virus from
causing serious illness in patients with weakened immune systems. For example, it could be used to
remove dormant HCMV infections from bone marrow before it is transplanted into a new individual.
DOI: 10.7554/eLife.06068.002
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KAP1 docking site (Groner et al., 2010). SETDB1 recruitment is stimulated by sumoylation of the KAP1
bromodomain, the last step of which is mediated intra-molecularly by an E3 ligase activity contained in
the PHD domain (Ivanov et al., 2007). Within the context of DNA damage, the ATM (ataxia
telangiectasia mutated) kinase phosphorylates KAP1 at position 824, resulting in decreased KAP1
sumoylation and SETDB1 recruitment, with secondary loss of KAP1 repressor activity (White et al.,
2006, 2012; Noon et al., 2010).
Histone 3 lysine 9 trimethylation and HP1 recruitment are thus signatures of KAP1 action.
Furthermore, we previously demonstrated that KRAB/KAP-mediated repression is functional within the
context of episomal DNA (Barde et al., 2009). Finally, the KRAB/KAP pathway has been found to
influence the replication of two members of the herpes virus family, Epstein–Barr virus (EBV) (Liao et al.,
2005) and Kaposi’s sarcoma-associated herpes virus (KSHV) (Chang et al., 2009; Cai et al., 2013).
Based on these premises, we investigated a possible role for KAP1 in the control of HCMV latency.
We found that KAP1 is a key mediator of this process, and that it is targeted by an mTOR-mediated
phosphorylation switch that can be exploited to force the virus out of latency. Our results suggest new
avenues not only for controlling HCMV infection but also for purging the virus from organ transplants.
Results
KAP1 is necessary for both establishment and maintenance of HCMV
latency in HSC
We first infected either MRC5 fibroblasts or cord blood-derived CD34+ cells with the TB40-E HCMV
clinical strain. Monitoring the levels of viral DNA and various RNA transcripts during the following days
confirmed that lytic replication occurred in MRC5 cells, known to be fully permissive, whereas latency
was established in HSC after an initial outburst of viral gene expression (Figure 1—figure supplement
1A,B), as previously reported (Goodrum et al., 2007). To examine the possible impact of KAP1 on
this process, we depleted the corepressor by lentivector-mediated RNA interference, complementing
Kap1 knockdown cells by transduction with a vector expressing an shRNA-resistant Kap1 allele when
relevant. We then infected these cells with TB40-E HCMV. In MRC5 cells, where KAP1 depletion
was around 98% (Figure 1—figure supplement 2A), levels of viral transcripts indicative of a lytic cycle
(the IE genes UL123, UL122, the E gene UL54 and the L gene UL94) were comparable in control and
KAP1-depleted cells (Figure 1A) and production of viral proteins IE1 and IE2 was unchanged
(Figure 1—figure supplement 2B), indicating that the regulator is not essential for productive HCMV
replication. In unsorted population of HSC exposed to the knockdown lentivector, KAP1 reduction
was only 85% but in sorted CD34+ GFP-positive, that is, transduced cells, it reached 95%
(Figure 1—figure supplement 2C,D). In this KAP1-depleted subpopulation, expression of
immediate early, early and late viral genes at 7 days post-infection was increased between 10- and
35-fold compared with control cells (Figure 1B), and massive amounts of infectious HCMV particles were
released in the supernatant (Figure 1C). Furthermore, complementation of KAP1-depleted cells with an
shRNA-resistant Kap1 allele restored HCMV latency (Figure 1—figure supplement 2E–I). These results
thus indicated that KAP1 is necessary for the establishment of HCMV latency in HSC. We then inverted
the sequence of our manipulations to induce Kap1 knockdown in CD34+ cells that had been infected
7 days earlier with the TB40-E virus (Figure 1—figure supplement 2J). 7 days after transduction, we
measured the expression of the UL122, UL123, UL54 and UL94 mRNAs, which are found only during
a lytic cycle (Reeves and Sinclair, 2013) (Figure 1D). All transcripts were significantly upregulated
in knockdown cells, which accordingly released infectious viral particles (Figure 1E). Furthermore, the
NF-κB activator TNFα increased viral gene expression and virion production from Kap1 knockdown but
not from control TB40-E-infected CD34+ cells (Figure 1D,E). These data indicate that (i) KAP1 is
necessary both for the establishment and for the maintenance of HCMV latency in human HSC, and (ii)
the relief of KAP1-mediated repression is not in itself sufficient for full HCMV reactivation in CD34+ cells,
but provides the ground for stimulation of viral gene expression by HCMV activators such as NF-κB.
HCMV latency in HSC correlates with KAP1-mediated recruitment of
SETDB1 and HP1α and with H3K9 trimethylation
Cells in which HCMV expression was induced following KAP1 depletion kept expressing the CD34
stem cell marker, indicating that viral activation was not simply due to their differentiation into
normally permissive cells such as activated DCs or macrophages. Still, as KAP1 exerts pleomorphic
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effect on hematopoiesis (Barde et al., 2013), we could not exclude that its depletion induced HCMV
lytic genes expression through indirect effects. We thus asked whether the co-repressor associates
with the HCMV genome by performing KAP1-specific chromatin immunoprecipitation-deep
sequencing (ChIP-seq) analyses on material isolated from human CD34+ HSC at 7 days post-TB40-E
Figure 1. KAP1 is required for HCMV latency. RT-qPCR analysis of indicated HCMV genes expression in MRC-5
(A) or cord blood CD34+ (B, C, D, E) cells infected with the TB40-E strain 3 days after (A, B, C) or 7 days prior to (D, E)
being transduced or not (NT) with lentivectors expressing (shKAP1) or not (empty) a small hairpin RNA against Kap1,
sorting CD34+ cells for GFP and CD34 expression. RT-qPCRs were performed 7 days after HCMV infection (A and B)
or 7 days after lentiviral transduction (D and E). Results are presented as average of fold change expression vs NT
after GAPDH and β-2M normalization (n = 4, *p < 0.05, **p < 0.01, error bars as s.d.). (C and E) HCMV production in
CD34+ cells was quantified by plaque assay on MRC-5 cells. Results are presented as average of PFU/ml (n = 3, *p <
0.05, **p < 0.01, ***p < 0.001, error bars as s.d.). See Figure 1—figure supplements 3, 4 for all individual
experiments.
DOI: 10.7554/eLife.06068.003
The following figure supplements are available for figure 1:
Figure supplement 1. KAP1 is necessary for both establishment and maintenance of HCMV latency in HSC.
DOI: 10.7554/eLife.06068.004
Figure supplement 2. KAP1 is necessary for both establishment and maintenance of HCMV latency in HSC.
DOI: 10.7554/eLife.06068.005
Figure supplement 3. KAP1 is necessary for establishment of HCMV latency in HSC.
DOI: 10.7554/eLife.06068.006
Figure supplement 4. KAP1 is necessary for maintenance of HCMV latency in HSC.
DOI: 10.7554/eLife.06068.007
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infection. Using a stringent peak-calling algorithm and validating its results by ChIP-PCR, we identified
28 major KAP1-enriched regions on the HCMV genome (Figure 2A,B and Supplementary file 1).
Supporting the functional significance of KAP1 recruitment to latent HCMV genomes, ChIP-PCR
analyses also detected SETDB1, H3K9me3 and HP1α at these KAP1-enriched regions (Figure 2C and
Figure 2—figure supplement 1A). Furthermore, in line with our former demonstration that
heterochromatin formation can spread several tens of kilobases away from primary KAP1 docking
sites (Groner et al., 2010), H3K9me3 and HP1α were found at significant distances from these major
KAP1 peaks, and particularly covered the major immediate early promoter (MIEP), the viral origin of
lytic replication (OriLyt) and the UL112 gene. In contrast, the repressive mark was not found at genes
known to be expressed during latency such as UL138 or LUNA (Reeves and Sinclair, 2013) (Figure 2D
and Figure 2—figure supplement 1B). Importantly, SETDB1 and HP1α recruitment as well as H3K9
trimethylation were lost when KAP1 was depleted by RNA interference prior to HSC infection,
supporting a model whereby the corepressor recruits these heterochromatin-inducing factors
(Figure 2—figure supplement 1A–D).
An mTOR-mediated KAP1 phosphorylation switch between HCMV
latency and lytic replication
We then examined the epigenetic status of HCMV genome when TB40-E-infected CD34+ cells were
differentiated in mature dendritic cells (mDCs), a procedure previously demonstrated to result in HCMV
activation. As expected, the TB40-E DNA was no longer associated with SETDB1 or HP1α and did not
bear the H3K9me3 repressive mark in the CD34-derived mDCs (Figure 3A and Figure 2—figure
supplement 1A). However, KAP1 was surprisingly still associated with the viral genome in these targets
(Figure 3B). The same pattern was recorded in TB40-E infected MRC-5 cells, where the virus achieves
a complete lytic cycle (Figure 3—figure supplement 1A,B). It suggested that HCMV reactivation and
replication could occur in spite of corepressor binding. To probe this issue further, we infected
CD34+ cord blood and MRC5 cells with the HCMV AD169 laboratory strain, which is incapable of
inducing latency (Goodrum et al., 2007; Saffert et al., 2010). At day 7 post-infection, while the
productively transcribed AD169 genome carried as expected neither SETDB1 nor H3K9Me3, it
was still bound by KAP1 in both cell types as robustly as the latent TB40-E strain in HSC
(Figure 3—figure supplement 1C,D). Therefore, it is not KAP1 recognition but rather the secondary
recruitment of its SETDB1 effector and other KAP1-associated heterochromatin inducers such as
HP1, which is responsible for HCMV latency.
Within the context of DNA damage, ATM phosphorylates KAP1 on serine 824, thereby reducing its
ability to bind SETDB1 hence its repressor potential (White et al., 2006, 2012; Noon et al., 2010).
We thus asked whether this modification could alter the consequences of KAP1 recruitment to the
HCMV genome. We could immunoprecipitate the TB40-E DNA with pS824KAP1-specific antibodies in
HCMV-reactivated mDC but not in latently infected HSC, with a pattern of genomic recruitment
identical to that delineated with the global KAP1 antibody in both cell types (Figure 3C,D).
Furthermore, pS824KAP1 was similarly found associated with the replicating AD169 viral DNA in both
MRC5 cells and CD34+ HSC (Figure 3—figure supplement 1E,F) and with the TB40-E-genome in
productively infected MRC-5 fibroblasts (Figure 3—figure supplement 1G). Confirming these data,
immunofluorescence detected the presence of pS824KAP1 in 100% of TB40-E- or AD169-infected MRC-5
fibroblasts, but not in uninfected fibroblasts (Figure 4A,B–D and Figure 4—figure supplement 1A), nor
in CD34+ HSC latently infected with the TB40-E strain, which could be identified by their loss of expression
of the surface protein MRP1 as recently described (Weekes et al., 2013) (Figure 4E).
We then set to identify the kinase responsible for phosphorylating KAP1 in cells productively
infected with HCMV. The ATM inhibitor KU55933 did not prevent this process, suggesting that this
known KAP1 kinase did not play a primary role (Figure 4—figure supplement 1B). We thus turned to
the mammalian target of rapamycin (mTOR), which was previously found activated in cells replicating
HCMV (Moorman and Shenk, 2010; Clippinger et al., 2011; Clippinger and Alwine, 2012;
Poglitsch et al., 2012). When TB40-E infected MRC-5 cells were treated with the mTOR inhibitors
rapamycin or Torin1 (Thoreen and Sabatini, 2009; Thoreen et al., 2009), the phosphoKAP1-specific
immunofluorescence signal was suppressed (Figure 4C and Figure 4—figure supplement 1C),
whereas total levels of KAP1 were unaffected (Figure 4—figure supplement 1D). Torin1-preventable
pS824KAP1 accumulation was also documented in CD34+ HSC infected with the replicative AD169
strain (Figure 4D and Figure 4—figure supplement 1E,F). In this setting, the IE protein-specific
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Figure 2. KAP1, SetDB1 and H3K9Me3 are enriched on the HCMV genome in latently infected HSC. (A) KAP1 binding sites on HCMV genome in
TB40-E-infected CD34+ cells, mapped by ChIP-Seq performed at day 7 post-infection. Results are presented as hit point upper 120 on the
reference sequence GenBank EF999921.1, indicating all KAP1 peaks (1–28). (B and C) ChIP-PCR with anti-KAP1 (B), anti-SetDB1 and anti-H3K9Me3
(C) antibodies were performed on ChIP-Seq-mapped KAP1 peaks (1–28) plus two KAP1-negative HCMV regions (Neg 1 and 2), using EVX-1 and
GAPDH as negative cellular gene controls, and ZNF180 and RP11-517P14.7 as positive controls. (D) H3K9me3-specific ChIP-PCR of two latency
Figure 2. continued on next page
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signal was reduced by the mTOR inhibitor, consistent with some repression of viral gene expression.
Of note, some KAP1 phosphorylated on serine 473 was detected in MRC5 cells, but this was
independent of HCMV infection and Torin1-resistant (Figure 4—figure supplement 2A–C). In
contrast, recombinant mTOR could phosphorylate GST-KAP1 on S824 in vitro (Figure 4—figure
supplement 2D).
Cell fractionation analyses indicated that pS824KAP1 accumulated in the nucleus of CMV-infected
cells, which also displayed increased levels of phospho-S6 ribosomal protein, a marker of mTOR
activation (Figure 5A). Indirect immunofluorescence and confocal microscopy further revealed mTOR-
specific foci in the nucleus of TB40- or AD169-infected but not control MRC5 cells (Figure 5B and
Figure 5—figure supplement 1A). Finally, ChIP with an mTOR-specific antibody demonstrated that
the kinase associated with the CMV genome at the same places regions as pS824KAP1 (Figure 5C).
Consistent with a restriction of KAP1 phosphorylation and inactivation to CMV-associated molecules,
the corepressor could still mediate the transcriptional silencing of an integrated TetO-PGK-GFP
cassette via a Tet repressor-KRAB fusion protein (Wiznerowicz and Trono, 2003) in virus-infected
cells (Figure 5—figure supplement 1B).
Forcing HCMV out of latency by pharmacological manipulation of KAP1
These results suggested that HCMV silencing might be amenable to suppression by pharmacolog-
ically induced KAP1 phosphorylation. In the absence of strictly specific mTOR activator, we turned to
ATM, a kinase previously demonstrated as capable of phosphorylating KAP1 on S824 (White et al.,
2012). When HSC infected 5 days earlier with TB40-E were incubated with the ATM activator
chloroquine (Bakkenist and Kastan, 2003), intracellular levels of viral RNAs and DNA increased
(Figure 6A,B), and infectious viral particles were released in the supernatant (Figure 6C). Supporting
the specificity of the observed phenomenon, Torin-1 did not block chloroquine-induced HCMV RNA,
DNA and viral particle production, whereas the ATM inhibitor Ku55933 prevented this process
(Figure 6). These results obtained in a first set of HSC obtained from three donors were confirmed in
another group of three donors, where it was further observed that levels of viral transcripts increased
in drug-treated cells only transiently after a single dose of drug but steadily if three doses were
administered over 5 days (Figure 6—figure supplement 1A), and that single doses of the ATM
activator prevented the progressive drop in viral DNA that was observed in control cells, while
repeated doses triggered an augmentation in viral DNA copies, indicative of genome replication
(Figure 6—figure supplement 1B). Correlating these quantitative virological data, chloroquine
treatment allowed the detection by immunofluorescence of pS824KAP1-positive cells (Figure 6—figure
supplement 1C). These were also systematically positive for IE antigens (Figure 6—figure supplement
1C), confirming that the virus harbored by these cells had exited latency. Finally, when the supernatant of
TB40-E-infected HSC exposed to chloroquine was used to inoculate MRC5 fibroblasts, it induced the
accumulation of viral DNA in these targets (Figure 6—figure supplement 1D), demonstrating that the
production of replication-competent virus had been induced by ATM-activating treatment of the latently
infected HSC. Noteworthy, pS824KAP1 was detected only in HCMV IE-positive cells, which strongly
suggests that KAP1 became phosphorylated in these cells through the combined action of ATM and
some HCMV-encoded factor. Importantly, these effects were induced without drop in KAP1 levels or loss
of surface expression of the CD34 stem cell marker (Figure 6—figure supplement 2A,B). Additional
evidence strongly suggested that chloroquine stimulated HCMV via KAP1 phosphorylation. First, the
drug did not further boost TB40-E in MRC-5 cells, where viral replication is KAP1-insensitive
(Figure 6—figure supplement 2C,D). Second, it did not further stimulate HCMV gene expression
and virion release in CD34+ cells depleted for KAP1, whether or not these were complemented
Figure 2. Continued
genes (UL138, LUNA) and three regions active during lytic replication (OriLyt, UL112 and MIEP), with the same controls as in (C). Results are
presented as total input fold enrichment (EVX-1 normalized).
DOI: 10.7554/eLife.06068.008
The following figure supplement is available for figure 2:
Figure supplement 1. KAP1-dependent recruitment of HP1α and SETDB1 with H3K9 trimethylation of HCMV genome in latently infected HSC.
DOI: 10.7554/eLife.06068.009
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with a phosphorylation resistant S824A KAP1 mutant (Figure 6—figure supplement 3A,B and
Figure 6—figure supplement 4AB). Third, and by contrast, chloroquine did reactivate HCMV
when these knockdown cells were complemented with wild-type KAP1 (Figure 6—figure
supplement 4A,B).
We also asked whether the pharmacological induction of KAP1 phosphorylation could trigger
HCMV production from circulating monocytes. Monocytes were purified from the peripheral blood of
seropositive individuals and exposed to three doses (at days 0, 3 and 5) of chloroquine, alone or in
combination with Torin-1 or KU55933 (Figure 7). ATM activation did not trigger the differentiation of
the monocytes into dendritic cells or macrophages, as verified by measuring the cell surface
expression of CD1a, CD14, CD80 and CD86 (Figure 7—figure supplement 1). However, it induced
the intracellular accumulation of HCMV DNA and the release of infectious viral particles from these
monocyte populations. Furthermore, Ku55933 but not Torin-1 prevented the stimulating effect of
chloroquine, as noted in HSC.
Figure 3. A KAP1 phosphorylation switch governs HCMV progression from latency to lytic replication. ChIP-PCR of indicated HCMV genomic regions was
performed with anti-SetDB1 and anti-H3K9Me3 (A), anti-KAP1 (B) or anti- S824 phosphoKAP1 antibodies (C and D) on material extracted from TB40-E-
infected cells CD34+ cells (C) or mature dendritic cells derived therefrom (A, B, D), using same controls as in Figure 2. Results are presented as total input
fold enrichment after EVX-1 normalization.
DOI: 10.7554/eLife.06068.010
The following figure supplement is available for figure 3:
Figure supplement 1. A KAP1 phosphorylation switch distinguishes HCMV latency and lytic replication.
DOI: 10.7554/eLife.06068.011
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These data demonstrate that inducing KAP1 phosphorylation results in releasing HCMV from its
latent state by relieving repressive marks on the viral chromatin. Nevertheless, levels of viral gene
expression achieved in this setting remain lower than observed when HCMV-harboring precursors are
differentiated into macrophages or mature dendritic cells, where NF-κB has been demonstrated to
drive viral transcription. We thus exposed latently infected CD34+ cells to chloroquine and TNF- α
(5 ng/ml), either alone or in combination (Figure 8). With TNF alone, HCMV transcription was not
induced, indicating that the virus remained latent. With chloroquine alone, significant induction of cell-
associated viral transcripts (approx. 100-fold) and DNA (approx. fivefold) was measured, and viral
particles were released in the supernatant (10,000 PFU/ml in the experiment depicted in Figure 8).
With the further addition of TNF, levels of CMV-specific RNAs increased by another 10-fold, the
amounts of cell-associated viral DNA doubled, and virion production was boosted by a factor 10.
Figure 4. mTOR inhibition prevents HCMV-induced KAP1 phosphorylation. MRC-5 (A, B, C) and CD34+ (D and E) cells, infected (AD169 or TB40-E) or not
(Non Infected) with HCMV, and treated or not (Non Treated) with mTOR inhibitor (Torin1) were examined by immunofluorescence with anti-IE and anti-
MRP1 antibodies (Alex-488, green), and anti-S824 phosphoKAP1 antibodies (Alexa 568, red). DNA was stained with Dapi (blue). White arrows represent
latently infected cells (MRP-1 negative cells). Scale Bar in white represents 10 μm for MRC-5 and 5 μm for CD34+. All pictures are representative of slide
overview from three independent experiments.
DOI: 10.7554/eLife.06068.012
The following figure supplements are available for figure 4:
Figure supplement 1. mTOR and HCMV-associated KAP1 phosphorylation.
DOI: 10.7554/eLife.06068.013
Figure supplement 2. mTOR and HCMV-associated KAP1 phosphorylation.
DOI: 10.7554/eLife.06068.014
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Figure 5. mTOR associates with the HCMV genome during lytic replication. (A) MRC-5 cells were infected 3 days (TB40-E) or not (NT) with HCMV and
harvested for cell fractionation. IE1/2, α-Tubulin, KAP1, KAP1 pS824, Histone 3 and phosphorylated or not S6 ribosomal protein expression/localization in
Total extract, cytosolic (soluble) nuclear (insoluble) and chromatin (chromatin) parts were analysed by Western-Blot. (B) Immunofluorescence by confocal
microscopy was performed on MRC-5, HCMV infected (TB40-E, AD169) or not (Non Infected). Staining was performed with anti-IE (Alex-488, green), and
Figure 5. continued on next page
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Importantly, this dual treatment did not trigger the differentiation of the HSC (Figure 8—figure
supplement 1). Taken together, these results suggest a model whereby chloroquine treatment
renders the HCMV chromatin permissive for transcription through KAP1 S824 phosphorylation, which
then allows TNF to induce full viral gene expression via NF-kB activation.
Discussion
This work sheds light on the mechanisms of HCMV persistence by revealing that, in latently infected
hematopoietic stem cells, the master co-repressor KAP1 recruits HP1α and SETDB1 to the viral
genome, triggering H3K9 methylation and heterochromatin formation. Our results correlate with the
observation that, in latently infected CD34+ HSC or circulating monocytes isolated from seropositive
individuals, chromatin at the HCMV MIEP bears H3K9me3 and HP1 (Sinclair, 2010). Our finding that
KAP1 partakes in both the establishment and the maintenance of HCMV latency also corroborates the
previously noted absence of more permanent silencing marks, such as DNA methylation, on latent
HCMV genomes (Hummel et al., 2007). We provide another important clue to the understanding of
HCMV biology by revealing that the virus exits latency when KAP1 becomes phosphorylated on serine
824, which blocks its ability to recruit SETDB1 hence abrogates its co-repressor potential. We further
identify mTOR as responsible for this KAP1 phosphorylation switch, and capitalizing on these findings
we finally demonstrate that HCMV can be forced out of latency by pharmacological activation of ATM,
another KAP1 kinase, and that this effect can be potentiated by adding TNF, an inducer of NF-kB.
Whether KAP1 phosphorylation relieves HCMV from latency only by dislodging SETDB1 and HP1 from
the viral chromatin or through more active mechanisms remains to be determined. Interestingly,
a small molecule inhibitor of LSD1/KDM1A was recently found to decrease HCMV immediate early
gene transcription (Liang et al., 2013). It could be that pS824KAP1 plays a role in attracting this H3K9
demethylase to the viral genome.
There are remarkable analogies but also interesting differences between our results and recent
data implicating KAP1 in the control of KSHV latency (Chang et al., 2009; Cai et al., 2013). In cells
harboring latent KSHV genomes, KAP1, HP1 and H3K9me3 were enriched at more than two thirds of
viral promoters, and KAP1 knockdown reduced these repressive marks and stimulated virus production.
Furthermore, upon induction of a lytic cycle by overexpression of the Rta viral transactivator, KAP1
dissociated from the viral genome, resulting in loss of HP1 and H3K9me3. This correlated with
phosphorylation of KAP1 on S824, apparently mediated by the viral kinase vPK, with reciprocal decrease
in the level of KAP1 sumoylation (Chang et al., 2009). Here, while we find that a KAP1 phosphorylation
switch can also force HCMV out of latency, we demonstrate that, with this virus, the phosphorylated
form of the master repressor remains associated with actively transcribed viral genomes. Furthermore,
we implicate the cellular kinase mTOR in KAP1 phosphorylation. It was previously noted that both the
mTORC1 (mTOR complex 1) and mTORC2 (mTOR complex 2) arms of the mTOR pathway are activated
during lytic HCMV replication (Kudchodkar et al., 2004, 2006, 2007). This results in phosphorylating
notably the eukaryotic initiation factor 4E (eIF4E)-binding protein (4E-BP1) and the p70S6 kinase (S6K),
which enhances viral protein translation and more generally minimizes cellular stress responses
(Clippinger et al., 2011; Poglitsch et al., 2012). Here, we identify KAP1 as another substrate of this
cascade, by observing that (i) the co-repressor is phosphorylated on serine 824 in cells productively
infected with HCMV; (ii) this process is inhibited by the mTOR inhibitors rapamycin and Torin1; and
(iii) mTOR targets the viral chromatin at KAP1-bearing genomic sites during a lytic cycle. Conversely, we
could force HCMV out of transcriptional dormancy by inducing the activation of ATM, another kinase
targeting KAP1 on serine 824, in latently infected HSC and circulating monocytes. Nevertheless, our
data also point to the role of viral factors in targeting this process. First, S824 phosphoKAP1 was
Figure 5. Continued
anti-mTOR antibodies (Alexa 568, red). DNA was stained with Dapi (blue). Scale Bar in white represents 5 μm. (C) ChIP-PCR for indicated HCMV genomic
regions were performed with anti-mTOR or control-IgG on material extracted from TB40-E-infected MRC-5. Results are presented as total input fold
enrichment after HCMV Neg1 region normalization.
DOI: 10.7554/eLife.06068.015
The following figure supplement is available for figure 5:
Figure supplement 1. mTOR nuclear translocation and KAP1 activity in HCMV replicating cells.
DOI: 10.7554/eLife.06068.016
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Figure 6. Forcing HCMV out of latency in CD34+ cells by KAP1 pharmacological manipulation. After 5 days of infection
with TB40-E, CD34+ cells were treated three times (Day 0, 3 and 5) or not (NT) with Chloroquine (Chloro) alone or in
combination with the mTor inhibitor Torin-1 (Torin) or the ATM inhibitor KU59933 (KU). (A) Indicated HCMV transcripts
were quantified by RT-qPCR, using GAPDH and β-2 microglobulin for normalization. (B) HCMV DNA associated with
the TB40-E-infected HSC was quantified by qPCR, normalizing with the GAPDH and albumin genes. Data are
presented as average of three different experiments performed with cells from independent donors. (C) Supernatant
from the TB40-E-infected CD34+ cells, harvested after 7 days of treatment and the viral production was quantified by
classical plaque assay on MRC-5 fibroblasts. Results are presented as PFU/ml. Histogram represents an average of
three different experiments performed with HSC from three independent donors (n = 3, *p < 0.05, **p < 0.01, error
bars as s.d.). See Figure 6—figure supplements 5, 6 for all individual experiments.
DOI: 10.7554/eLife.06068.017
The following figure supplements are available for figure 6:
Figure supplement 1. HCMV can be forced out of latency in CD34+ cells by pharmacological manipulation.
DOI: 10.7554/eLife.06068.018
Figure supplement 2. HCMV can be forced out of latency in CD34+ cells by pharmacological manipulation.
DOI: 10.7554/eLife.06068.019
Figure supplement 3. HCMV can be forced out of latency in CD34+ cells by pharmacological manipulation.
DOI: 10.7554/eLife.06068.020
Figure supplement 4. HCMV can be forced out of latency in CD34+ cells by pharmacological manipulation.
DOI: 10.7554/eLife.06068.021
Figure supplement 5. HCMV can be forced out of latency in CD34+ cells by pharmacological manipulation.
DOI: 10.7554/eLife.06068.022
Figure supplement 6. HCMV can be forced out of latency in CD34+ cells by pharmacological manipulation.
DOI: 10.7554/eLife.06068.023
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detected only in HCMV IE antigen-positive cells. Second, KAP1 conserved its ability to repress a
chromosomal target in cells where its HCMV silencing activity was abrogated by phosphorylation.
This strongly suggests that mTOR is targeted to the HCMV genome, where the viral DNA-associated
KAP1 molecules are then exposed to its action, a model supported by the results of our mTOR-specific
chromatin immunoprecipitation. Such spatial compartmentalization would not be unprecedented, as
site-specific KAP1 phosphorylation is also observed in case of DNA damage (White et al., 2006), and as
mTOR has itself been observed to be directed to sites of HCMV assembly (Clippinger and Alwine,
2012). More generally, it will be interesting to ask whether the KRAB/KAP1 pathway contributes to the
latency of other herpes viruses, even though in the case of EBV the only evidence available so far is that
it instead promotes viral DNA replication (Liao et al., 2005).
Latency is a dominant, cell type- and differentiation stage-specific mechanism (Saffert et al., 2010;
Goodrum et al., 2012), as it is limited to HSC and cells of the myeloid lineage such as monocytes, and
to HCMV clinical isolates (e.g., TB40-E) that contain genomic regions commonly deleted in latency-
incompetent laboratory strains (e.g., AD169) (Goodrum et al., 2007; Reeves and Sinclair, 2010;
Petrucelli et al., 2012). Our findings thus suggest that, in HSC, a latency-specific gene product
counters HCMV-induced mTOR-mediated KAP1 phosphorylation, for instance by either blocking the
kinase or by acting as or inducing a KAP1-specific phosphatase. This warrants investigations aimed at
elucidating this aspect, and at determining whether, when and, if so, downstream of what pathway
mTOR becomes activated and KAP1 phosphorylated during the differentiation of HSC towards
macrophages or activated DCs, the cells in which HCMV transcription becomes fully productive.
KAP1 is not a DNA-binding protein, and is classically tethered to given genomic loci, for instance
endogenous retroelements, by sequence-specific KRAB-ZFPs (Friedman et al., 1996;Wolf and Goff,
2009; Rowe and Trono, 2011; Castro-Diaz et al., 2014). By analogy, it is tempting to hypothesize
Figure 7. Inducing KAP1 phosphorylation releases HCMV from latency in monocytes. Monocytes from HCMV
seropositive donors were purified and treated three times (Day 0, 3 and 5) or not (NT) with Chloroquine (Chloro)
alone in combination with Torin-1 (Torin) or KU59933. (A) HCMV DNA associated with the monocytes was quantified
by qPCR, normalizing with the GAPDH and albumin genes. Data are presented as average of three different
experiments performed with cells from independent donors. (B) Supernatant from the monocytes, harvested after 7
days of treatment and the viral production was quantified by classical plaque assay on MRC-5 fibroblasts. Results are
presented as PFU/ml. Histogram represents an average of three different experiments performed with HSC from
three independent donors (n = 3, *p < 0.05, **p < 0.01, error bars as s.d.). See Figure 7—figure supplement 2 for
all individual experiments.
DOI: 10.7554/eLife.06068.024
The following figure supplements are available for figure 7:
Figure supplement 1. Monocytes do not differentiate during pharmacological reactivation of HCMV.
DOI: 10.7554/eLife.06068.025
Figure supplement 2. Monocytes do not differentiate during pharmacological reactivation of HCMV.
DOI: 10.7554/eLife.06068.026
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that members of the KRAB-ZFP family are also involved in recognizing the HCMV DNA. In support of
this model, KAP1 recruitment to the HCMV genome was lost when the KRAB-binding RBCC domain
was deleted (not illustrated). Since we detected close to thirty major KAP1 peaks on the HCMV DNA
and failed to identify a common motif amongst all these sequences, more than one DNA-binding
protein, whether or not KRAB-ZFP, is likely involved in docking the corepressor at these sites. In the case
of KSHV, the latency protein LANA is responsible for tethering sumoylated KAP1 and the KAP1-bound
Sin3A repressor to the Rta promoter, through its ability to interact with SUMO-2-bearing proteins. Upon
hypoxia, KAP1 is de-sumoylated and together with Sin3A is released from the KSHV genome, leading to
Figure 8. Combining KAP1 phosphorylation and NF-κB induction increases HCMV activation from latently infected
HSC. After 5 days of infection with TB40-E, CD34+ cells were treated three times (Day 0, 3 and 5) or not (NT) with
chloroquine (Chloro) in combination or not with 5 ng/ml of recombinant TNF-α (TNF). (A) Indicated HCMV
transcripts were quantified by RT-qPCR, using GAPDH and β-2 microglobulin for normalization. (B) HCMV DNA
associated with the TB40-E-infected HSC was quantified by qPCR, normalizing with the GAPDH and albumin genes.
Data are presented as average of three different experiments performed with cells from independent donors.
(C) Supernatant from the TB40-E-infected CD34+ cells, harvested after 7 days of treatment and the viral production
was quantified by classical plaque assay on MRC-5 fibroblasts. Results are presented as PFU/ml. Histogram
represents an average of three different experiments performed with HSC from three independent donors (n = 3,
*p < 0.05, **p < 0.01, error bars as s.d.). See Figure 8—figure supplements 2, 3 for all individual experiments.
DOI: 10.7554/eLife.06068.027
The following figure supplements are available for figure 8:
Figure supplement 1. Pharmacological activation of HCMV does not trigger CD34+ cells differentiation.
DOI: 10.7554/eLife.06068.028
Figure supplement 2. Pharmacological activation of HCMV does not trigger CD34+ cells differentiation.
DOI: 10.7554/eLife.06068.029
Figure supplement 3. Pharmacological activation of HCMV does not trigger CD34+ cells differentiation.
DOI: 10.7554/eLife.06068.030
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the activation of the LANA-associated HIF-1α, the inducible subunit of the hererodimeric HIF-1 (hypoxia-
induced factor 1), thus activating viral gene expression (Cai et al., 2013). By analogy, it could be that
a virally encoded product contributes to targeting KAP1 to the HCMV genome.
Our data have important clinical implications. First, it was recently noted that transplant recipients
placed on immunosuppressive regimens that included rapamycin were less likely to suffer serious
CMV-related complications than patients for whom this drug was omitted (Andrassy et al., 2012; Sabe´
et al., 2012). The present work indicates that this beneficial effect might stem at least in part from
a prevention of viral reactivation. This warrants further studies to assess the positive impact of this and
other mTOR inhibitors on the control of HCMV infection, whether after transplantation or in other
settings. Of note, a recent study demonstrated that rapamycin did not prevent HCMV reactivation from
latently infected dendritic cells in vitro (Glover et al., 2014). However, it could be that KAP1
phosphorylation was already established in this system, and that maturation of the DCs only resulted in
activating transcription factors that are strong stimulators of HCMV gene expression, such as NF-κB.
Our discovery that HCMV can be forced out of latency by pharmacological manipulation
suggests new avenues to eradicate infection by combining ATM and NF-κB activation with immune-
or drug-based approaches aimed at killing HCMV-infected cells. The systemic administration of
ATM and NF-κB activators may cause important side effects, and HCMV eradication is anyway
probably unnecessary in immuno-competent individuals. However, the ex vivo treatment of HCMV-
positive transplants, for instance bone marrow or HSC purified therefrom, could be readily
envisioned to purge latently infected cells prior to engraftment, notably in the high-risk setting of
HCMV-negative recipients.
Materials and methods
Cell culture and treatments
CD34+ cells from HCMV negative human cord blood were obtained from the Lausanne University
Hospital (Centre Hospitalier Universitaire Vaudois, CHUV, Switzerland) delivery room with proper
informed consent, layered on Ficoll gradient, purified with the CD34+ cell separation kit (Miltenyi
Biotec, Germany) and freshly used for experiments without freezing to avoid differentiation. CD34+
cells were stimulated for one day in X-Vivo 15 medium (Lonza, Switzerland) supplied with cytokines
(100 ng/ml of Flt-3 ligand, 100 ng/ml of SCF, 20 ng/ml of TPO, and 20 ng/ml of IL-6; Peprotech, Rocky
Hill, NJ) and 5% penicillin/streptomycin, maintained at a density of 5.105 cells/ml and transduced the
day after stimulation with lentiviral vector at a MOI of 100 as previously described (Barde et al., 2013),
washed 24 hr later and cultured in X-Vivo 15 medium, 50 ng/ml of Flt-3 ligand, 25 ng/ml of SCF and 20
ng/ml of TPO. MRC5 fibroblasts serum and 5% penicillin/streptomycin. MRC-5 fibroblasts were
transduced with a lentivector at a MOI of 10, 3 days before HCMV infection. Monocytes were purified
from HCMV seropositive donors buffy coat, obtained at the EFS (Etablissement Franc¸ais du Sang,
France), with CD14+ magnetic selection kit (Miltenyi Biotec). After 7 days of HCMV reactivation
treatment, non differentiation of cells was controlled by different marker expression by FACS (CD1a,
CD14, CD80, CD86) (Invitrogen, Carlsbad, CA). Cells were cultured in RPMI medium (invitrogen)
supplemented with 10% FCS and Peni/strep. The mTOR (Torin1 and rapamycin, Selleckchem,
Houston, TX) and ATM (KU55933, LuBioscience, Switzerland) inhibitors were used at 0.1 and 10 μM,
respectively, added 30 min before infection. The ATM activator (chloroquine, Sigma–Aldrich, St Louis,
MO) was used at 20 μM. The recombinant TNF-α (Peprotech) is used at 5 ng/ml.
Mature DC generation
After 10 days of TB40-E infection, CD34+ HSC were cultured for 7 days in X-VIVO-15 medium
supplemented with GM-CSF (100 ng/ml), TGF-β (0.5 ng/ml), Flt-3 ligand (100 ng/ml), SCF (20 ng/ml)
and TNF-α (50 U/ml) (all from peprotech). This treatment leads to generation of immature dendritic
cells that will be pushed to maturation with lipopolysaccharide (LPS, 50 ng/ml) treatment during 3 days,
as described in (Reeves et al., 2005).
Ethics statement
Cord blood was obtained after approval of the project by the local ethics committee, commission
cantonale d’ethique de la recherche sur l’etre humain, as protocol 146/10. When necessary, samples
were obtained following informed consent of the participants.
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Lentiviral vectors
pLKO vectors were purchased from Sigma–Aldrich and the puromycin was replaced by eGFP (pLKO-
shKAP1, pLKO-empty, pLKO-scramble). QuickChange II XL Site directed Mutagenesis Kit (Agilent
Technologies Santa Clara, CA) was used to mutate KAP1 Serine 824 into Glutamic Acid in a pFUT
plasmid containing a human Kap1 allele modified by nucleotide substitutions to resist to our shRNA.
Production and titration of lentiviral vectors was performed as previously described (Barde et al., 2011).
Viruses
The AD169 (ATCC, Manassas, VA) and TB40-E (a gift from G Herbein, Besanc¸on, France) HCMV strains
were used in this study. Virus stocks were generated in MRC5 or HUVEC cells, collecting particles
when cytopathic effects were >90%. Supernatants were clarified of cell debris by centrifugation at
1,500×g for 10 min, ultracentrifuged at 100,000×g for 30 min at 4˚C and stored at −80˚C until use.
Virus titers were determined by plaque assay on MRC5 cells using standard methods (MEM2X diluted
twofold with solution of 1.6% agarose). MRC-5 were infected at a MOI of 1, while CD34+ infection
were performed at a MOI of 5, 3 days after or 7 days before transduction with lentivectors.
Chromatin immunoprecipitation (ChIP)
Chromatin from 107 CD34+ was prepared and immunoprecipitated as in (Barde et al., 2013), with
KAP1- (Abcam, UK), H3K9me3- (Diagenode, Belgium), SETDB1- (Abcam) mTOR (Abcam) or S824
phosphoKAP1- (Abcam) specific antibodies. TB40-E infected CD34+ KAP1-ChIPed DNA was sent to
sequencing. The 50 bp reads for KAP1 IP and Total Input were mapped to the HCMV genome (TB40-
BAC4 GenBank accession EF999921.1) using the bowtie short read aligner version 0.12.7 (Langmead
et al., 2009) and allowing up to three mismatches over the whole length of the read. The signal of the
total input was then subtracted from the KAP1 IP signal using a custom made PERL program (see
Source code 1) and regions with similar signal were merged together. The resulting regions were
ranked according to their signal. The signal follows a normal distribution (tested with Shapiro–Wilk
normality test) thus we considered as enriched regions the extreme right part of the distribution. The
data discussed in this publication have been deposited in NCBI’s Gene Expression Omnibus and are
accessible through GEO Series accession number GSE53271 (http://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc=GSE53271). SYBR green qPCR was performed to quantify enrichment at specific loci. Total
Input Fold enrichment was quantified by the classical following calculation: 100 × 2^−(CT of ChIPed
DNA − CT of Total Input). Cellular promoters regions were used as negative (EVX-1; GAPDH) or positive
(ZNF-180; RP11-517P14.7) controls for PCR enrichment. 28 highly enriched peaks were found for the
HCMV TB40-E strain, and two negative regions were designed for qPCR controls.
ImmunoFluorescence
MRC-5 were cultured directly on coverslips. Around 2 × 105 CD34+ were attached to slides by
cytospinning with Shandon EZ Single Cytofunnel (Thermo Fisher Scientific, Waltham, MA). Cells were
then fixed and permeabilised with Methanol during 5 min at −20˚C, and saturated with PBS 5% FCS
during 2 hr at room temperature (RT). Primary staining with IE-, anti-S824 phopshoKAP1-, KAP1- mTOR (all
from Abcam) anti-KAP1 S473 phosphoKAP1 (BioLegend, San Diego, CA) specific antibodies was
performed in PBS 5% FCS at 4˚C overnight or 3 hr at RT, before addition of secondary antibodies
(Alexa-488 or -565) in PBS 5% FCS during 1 hr at RT. Dapi bath was performed during 10 min at RT,
and slides were mounted with Fluoromount-G (Southern Biotech, Birmingham, AL).
RT-PCR
Cells were sorted for GFP (control of transduction) and CD34 expression. RNA was extracted by Trizol
and reverse transcribed with Superscript II (both from Invitrogen) according to the manufacturer’s
instructions. All qPCR were performed with SYBR green mix (Roche, Switzerland). Primers used in this
work were designed by Primer Express software (Applied Biosystems) and their sequences are
available on Supplementary file 2.
Cell fractionation
Cells were washed two times with cold PBS and centrifuged. Pellets were resuspended in 500 μl
of cytop Buffer (Triton 0.25%, Tris HCl 10 mM, EDTA 5 mM, EGTA 0.5 mM and proteases
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inhibitor cocktail) and incubated 3–5 min on ice. After centrifugation, supernatant was kept
as soluble part (cytoplasm) and pellet were lysed with TNEN 250:0.1 buffer (NaCl 250 mM, Tris
HCl 50 mM, EDTA 5 mM, NP40 0.1% and proteases inhibitor cocktail) 20–30 min on ice.
After centrifugation, supernatants were kept as insoluble part (nucleus) and pellets were lysed in
Urea 8 M, 10 min at 95˚C to recover chromatin part. Total amount of protein was quantified by
BCA assay.
Western blot analyses
Cells lysates were subjected to SDS/PAGE on 4–12% polyacrylamide gels (Invitrogen). iBlots on
Nitrocellulose membrane (Invitrogen) were treated with KAP1- Histone 3- α-Tubulin- (Abcam) mTOR-
S6 ribosomal protein- phospho S6 ribosomal protein (Cell Signaling, Beverly, MA) and βactin-
(Calbiochem, San Diego, CA) specific antibodies, followed by polyclonal rabbit HRP-conjugated
antibody, and protein bands were detected by using an ECL-plus kit (Thermo-Scientific). Anti-
KAP1pS824 antibody was produced in rabbits using a KLH-MBS coupled peptide with the following
sequence: AcNH-CAG LSS QEL pSGG P-CONH2 from Eurogentec.
In vitro kinase assays
GST-KAP1 and 1 U of mTOR (475987 Millipore, Billerica, MA) were incubated in phosphorylation
buffer (25 mM Hepes pH 6.8, 10 mM MgCl2, 0.5 mM DTT, 200 μM ATT, 1× Complete protease
inhibitor cocktail from Roche, 1% BSA) in a total volume of 15 μl for 30 min with shaking at room
temperature. mTOR activity is inhibited with 100 nM of Torin1.
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